(Q37836898)

24 August 2017

1 reference

title

Immunotherapy of multifocal motor neuropathy (English)

1 reference

24 August 2017

1 reference

Filip Eftimov

1

1 reference

24 August 2017

Ivo N Van Schaik

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Expert Opinion on Biological Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

329-342

1 reference

European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Motor Neuropathy with Proximal Multifocal Persistent Conduction Block, Fasciculations and Myokymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Motor conduction block and high titres of anti-GM1 ganglioside antibodies: pathological evidence of a motor neuropathy in a patient with lower motor neuron syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Acute conduction block in vitro following exposure to antiganglioside sera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

In vitro effects of polyvalent immunoglobulin for intravenous use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Intravenous immunoglobulin and dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Multifocal motor neuropathy: response to human immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Axon loss is an important determinant of weakness in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

How long is IVIg effective in multifocal motor neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Long term follow up of multifocal motor neuropathy with conduction block under treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Adverse effects of intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Case-control study of thromboembolic events associated with IV immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

A syndrome of asymmetric limb weakness with motor conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Multifocal motor neuropathy with conduction block misdiagnosed as multiple entrapment neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Bilateral phrenic neuropathy as a presenting feature of multifocal motor neuropathy with conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Plasmapheresis in multifocal motor neuropathy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Therapeutic apheresis in Sweden: update of epidemiology and adverse events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Mycophenolate mofetil in dysimmune neuropathies: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Mycophenolate in treatment-resistant inflammatory neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Treatment of IgM antibody associated polyneuropathies using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Beneficial effect of rituximab monotherapy in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Multifocal motor neuropathy with conduction block: a study of 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

Multifocal motor neuropathy with and without conduction block: A single entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.548798

10.1517/14712598.2011.548798

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference